BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

NeuroTherm, Inc. Acquires Smith & Nephew Inc. Interventional Spine Pain Management Assets


4/8/2010 7:03:44 AM

WILMINGTON, Mass., April 7 /PRNewswire/ -- NeuroTherm announced today that they have acquired the Smith & Nephew PLC (NYSE: SNN; LSE: SN) Interventional Spine Pain Management assets from Smith & Nephew's subsidiaries. The acquired product line includes several innovative interventional spine pain products including the CDS Discography System, SPINECATH™ & ACUTHERM™ Catheters and a full radiofrequency product line. NeuroTherm will also be a distributor of the TRUCATH™ Injection System within the Interventional Spine Pain market.

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/neurotherm-acquires-smith--nephew-interventional-spine-pain-management-assets-89991457.html

"This acquisition made perfect sense for us, and will go a long way towards sustaining NeuroTherm's leading position in the interventional pain space," says Larry Hicks, President & CEO of NeuroTherm. "The Smith & Nephew product line is highly complementary to ours and significantly expands our product offering. This is an exciting opportunity that will enable us to offer a one-stop option for our customers," continues Hicks.

"We have set plans in place to combine the experience and product knowledge of the two worldwide sales teams to allow us to provide our global customer base with excellent products and a single point of contact," says Jos Kerstens, VP of International Sales. NeuroTherm actively sells interventional pain products into 58 countries around the world. "We remain focused on helping physicians expand their practice and offer improved patient care to patients who suffer from chronic pain," continues Kerstens.

NeuroTherm is a leading manufacturer of products used in the field of Interventional Pain, including radio frequency generators and related consumables used to treat chronic pain. The company was awarded a US Patent #7,574,257 in recognition of the first multi-lesion radiofrequency generator launch. NeuroTherm markets and sells to Interventional Pain, Interventional Radiology, Orthopedic and Foot & Ankle Specialists. Foot & Ankle Physicians use radiofrequency to treat pain associated with Plantar Fasciitis & Neuroma.

NeuroTherm is headquartered in Wilmington, Massachusetts with corporate offices in London and Amsterdam. Additional information about NeuroTherm can be found on at www.neurotherm.com

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies. Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2009 were $3.8 billion.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->